| Company Name: |
ShangHai Caerulum Pharma Discovery Co., Ltd.
|
| Tel: |
18149758185 |
| Email: |
sales-cpd@caerulumpharma.com |
| Products Intro: |
Product Name:1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid
CAS:1144504-35-7
Purity:98% Package:1g;10g;100g
|
| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:PQCA
CAS:1144504-35-7
Package:10mg，100mg，500mg，1g，2g，5g，10g，More
|
1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid manufacturers
- PQCA
-
- $47.00 / 1mg
-
2025-12-22
- CAS:1144504-35-7
- Min. Order:
- Purity: 99.88%
- Supply Ability: 10g
- PQCA
-
- $47.00 / 1mg
-
2025-12-05
- CAS:1144504-35-7
- Min. Order:
- Purity: 99.88%
- Supply Ability: 10g
|
| | 1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid Basic information |
| | 1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid Chemical Properties |
| Boiling point | 708.5±60.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 10 mg/mL (25.75 mM; ultrasonic and warming and heat to 80°C) | | form | Solid | | pka | 1.83±0.20(Predicted) | | color | White to yellow |
| | 1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid Usage And Synthesis |
| Uses | PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA is a novel M1 muscarinic potentiator that improves cognition without adverse effects compared to donepezil and xanomeline in rhesus monkey. | | in vivo | PQCA (3-30 mg/kg; oral administration; single- or pair-housed male rhesus monkeys) treatment attenuates the scopolamine deficits in PAL and CPT tasks. Blockade of muscarinic signaling by scopolamine produces significant impairments in both tasks[1]. | Animal Model: | Ten single- or pair-housed male rhesus monkeys (6-10 years old; 5.2-10.5 kg) with scopolamine[1] | | Dosage: | 3 mg/kg, 10 mg/kg, or 30 mg/kg | | Administration: | Oral administration | | Result: | Attenuated the scopolamine deficits in paired-associates learning (PAL) and the continuous-performance task (CPT).
|
|
| | 1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid Preparation Products And Raw materials |
|